Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics and Viatris, Inc. (Viatris) (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants ...
Ophthalmology Times

sNDA for phentolamine ophthalmic solution 0.75% from Opus Genetics accepted for review by FDA

Phentolamine is framed as a differentiated, preservative-free sympatholytic approach that modulates pupil dynamics without ciliary muscle activation, targeting near-vision improvement while ...
pix11

Opus Partners with Checkmarx to Deliver Enhanced Application Security

Checkmarx to deliver cutting-edge application security to its clients. ALPHARETTA, Ga., Sept. 26, 2023 /PRNewswire/ -- Opus, a global leader in payment technology solutions, has concluded a strategic ...
Seeking Alpha

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a ...